EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 741 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR Data Shows Women Are Not Getting Access To An Important Part... July 30, 2021 Cómo aprendí a sobrellevar la culpa del superviviente después del cáncer May 4, 2022 Breast Cancer Patient Is Accused of Having “Body Image Issues” After... March 5, 2021 One year on: How has COVID-19 affected cancer services? May 14, 2021 Load more HOT NEWS Sacituzumab Govitecan Demonstrates Significant Improvement in PFS in Heavily Pretreated, Locally... Breast Cancer Patient Devotes Her Time to Driving Others to Treatment A Subset of Patients with NSCLC Respond Poorly to the COVID-19... Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative...
